With the significant improvement in cancer prognosis, especially when checkpoint inhibitor drugs that target PD-1 or PD-L1 and boost the immune response against cancer cells show a great deal of promise in treating certain cancers, attention must be paid to the optimal management of the concomitant CVD in this population. The gene discussed is CD274; the disease is cancer.